Commission Implementing Regulation (EU) 2021/442 making the exportation of certain products subject to the production of an export authorisation

Summary:

Implementing Regulation (EU) 2021/442 - adopted by the European Commission on 11 March 2021 - introducing the extension to a measure requiring vaccine exports to be subject to an authorisation by Member States.

Further information:

The European Commission adopted in January 2021 the Implementing Regulation (EU) 2021/111, aimed at making exportation of COVID-19 vaccines as well as active substances, including master and working cell banks, used to manufacture these vaccines, subject to the production of an export authorisation. This export authorisation mechanism only applies to exports from companies with which the EU has concluded Advance Purchase Agreements (APAs).

This Act extends until the end of June 2021 the transparency and authorisation mechanism for COVID-19 vaccine exports. This regulation also simplifies the procedure by allowing the grouping of exports to different final recipients in the same country in one single request. It also provides clarity by identifying the customs codes for the active substances covered by the measure. It was published in the Official Journal on 12 March 2021.

Swyddogol

European Commission: Press Release, 11/03/2021: Commission extends transparency and authorisation mechanism for exports of COVID-19 vaccines https://ec.europa.eu/commission/presscorner/detail/en/ip_21_1121

---